Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

LILLY's CESAMET (NABILONE) LAUNCH AWAITS DEA SCHEDULING of the synthetic cannabinoid, Lilly said. Cesamet, which is chemically related to THC, was approved by FDA on Dec. 27 "for use in the treatment of nausea and vomiting associated with cancer chemotherapy." Lilly said the drug "is indicated for those patients who have failed to respond adequately to conventional anti-emetic treatment." A course of therapy "runs one to five days concomitantly with chemotherapy," Lilly said. Once scheduled by the Drug Enforcement Agency and introduced, Cesamet will compete with Unimed's Marinol (dronabinol or THC) which is approved for the same indication. Marinol, approved June 6, still has not come to market because of delays in DEA scheduling. Unimed President Paul Bollenbacher recently denied rumors that the DEA decided not to reclassify the marijuana-derived product from Schedule I to II. He explained that despite a six month delay, DEA "reassured" the firm of the agency's intent to reschedule the product to the less restrictive Shedule II ("The Pink Sheet" Dec. 16, "In Brief"). In April 1983, FDA's Drug Abuse Advisory Cmte. recommended that Cesamet be placed in Schedule III under the Controlled Substances Act. Despite FDA's position at that time that nabilone and THC are "essentially identical in abuse potential," the cmte. recommended Schedule III for Cesamet after having recommended Schedule II for THC. Cesamet is currently marketed as an anti-emetic in Canada and the U.K. Those approvals were granted in 1982 and 1983, respectively. Lilly noted that it will not determine the price of Cesamet until the product clears DEA.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts